Lowering Phosphate Levels in End-Stage Kidney Disease
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Recruiting
N/A
Interventional Study
Kidney Failure, Chronic
Hyperphosphatemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3,600 (estimated)
- Sponsor
- The University of Queensland · Other
Who this trial is looking for
This trial is looking for adults with end-stage kidney disease who are on dialysis and taking phosphate-lowering medication. Participants will help researchers understand if lowering phosphate levels can improve health and reduce serious health events.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 45 years old, or at least 18 years old with diabetes.
- I have end-stage kidney disease and have been on dialysis for at least 3 months.
- I am currently prescribed at least one phosphate-lowering medication.
- I can provide consent to take part in the trial.
You may not be able to join if
- I have an elective kidney transplant scheduled.
- My doctor believes I have a major illness that could lead to death in the next 6 months.
- I am participating in another study that affects phosphate levels.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, an…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥45 years, or Age ≥18 years with diabetes,
2. ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,
3. Currently prescribed at least one phosphate-lowering medication at any dose
4. Able to provide informed consent
Exclusion Criteria:
1. Elective kidney t…
Contacts